Research Journal of Pharmacy and Technology

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Pharmacokinetic Drug Interactions Between HMG-COA Reductase Inhibitors Fluvastatin with Concomitantly Administered Ticagrelor


Affiliations
1 Mewar, University, Chittorgarh, Rajasthan, India
2 Mewar University, Chittorgarh, Rajasthan, India
     

   Subscribe/Renew Journal


The present study was aimed to carry out any possible pharmacokinetic interactions between fluvastatin and ticagrelor. Study was conducted in Male Wistar rats; animals were divided in to three groups, Group I: Fluvastatin alone in single dose / day in healthy rats. Group II: ticagrelor alone in single dose / day in healthy rats. Group III: Fluvastatin and ticagrelor concomitant administration in healthy rats as a single dose / day. And the treatment was given on day one and day 8 both alone Fluvastatin and ticagrelor and concomitantly used both the drugs. The results were showed no significant difference in the tmax of Fluvastatin alone and combination with ticagrelor on day 1 and day 8 respectively. These were no significant difference in both cmax and tmax of ticagrelor alone and combination of Fluvastatin on day 1 and day 8 respectively. And there was no significance difference in AUC0-t and AUCo-inf also in alone and combination of both drugs on day 1 and day 8th. Based on the results obtained from kinetic study it is evident that the single dose of Fluvastatin with ticagrelor individually and concomitantly treated shows no statistically significant interactions in its pharmacokinetic parameters

Keywords

Fluvastatin, Ticagrelor, Pharmacokinetic Parameters.
Subscription Login to verify subscription
User
Notifications
Font Size


  • Ament, P.W; Bertolino, J.G.; Liszewski, J.L. Clinically significant drug interactions. Am. Fam.Phys.2000, 61, 1745–1754.

  • Alfaro, C.L.; Piscitelli, S.C. Drug Interactions. In Principles of Clinical Pharmacology; Atkinson, A.J., Daniels, C.E., Dedrick, R.L, Grudyinllas, C.U., Markey, S.P., Eds; Academic Press: San Diego, CA, USA, 2001; pp. 167–180.

  • Anastasio, G.D.; Cornell, K.O.; Menscer, D. Drug interactions: Keeping it straight. Am. Fam. Phys. 1997, 56, 883–894.

  • Hohl, C.M; Dankoff, J; Colacone, A; Afilalo, M. Polyparmacy adverse drug-related events, and potential adverse drug interactions in elderly patients presenting to an emergency department. Ann. Emerg. Med. 2001, 38, 666–671.

  • Wright, J.M. Drug Interactions. In Melmon and Marrelli’s Clinical Pharmacology Basic Principles in Therapeutics, 4th ed.; Carruthors, S.G, Hoffman, B.B, Melmon, K.L, Nierenberg, D.W, Eds; McGrow-Hill: New York, NY, USA, 2000; pp. 1257–1266.

  • Hogan, M.J; Zucchero, F.J; Schulty, C.D; Curran, J.P. Drug Store News (Serial Online) August 1999. Available online: http://www.fmdarticles.com (accessed on 20 January 2004.

  • Rama Rao Vunnam, Sriharsha S. N, V. V. Rajesham, pharmacokinetic drug interactions of gliclazide and itopride in normal and diabetic rats, International Journal of Pharmacy and Pharmaceutical Sciences, (2015), 7(10), 2015, 307-311.


Abstract Views: 189

PDF Views: 0




  • Pharmacokinetic Drug Interactions Between HMG-COA Reductase Inhibitors Fluvastatin with Concomitantly Administered Ticagrelor

Abstract Views: 189  |  PDF Views: 0

Authors

M. A. Hakeem Siddiqui
Mewar, University, Chittorgarh, Rajasthan, India
S. Roshan
Mewar University, Chittorgarh, Rajasthan, India

Abstract


The present study was aimed to carry out any possible pharmacokinetic interactions between fluvastatin and ticagrelor. Study was conducted in Male Wistar rats; animals were divided in to three groups, Group I: Fluvastatin alone in single dose / day in healthy rats. Group II: ticagrelor alone in single dose / day in healthy rats. Group III: Fluvastatin and ticagrelor concomitant administration in healthy rats as a single dose / day. And the treatment was given on day one and day 8 both alone Fluvastatin and ticagrelor and concomitantly used both the drugs. The results were showed no significant difference in the tmax of Fluvastatin alone and combination with ticagrelor on day 1 and day 8 respectively. These were no significant difference in both cmax and tmax of ticagrelor alone and combination of Fluvastatin on day 1 and day 8 respectively. And there was no significance difference in AUC0-t and AUCo-inf also in alone and combination of both drugs on day 1 and day 8th. Based on the results obtained from kinetic study it is evident that the single dose of Fluvastatin with ticagrelor individually and concomitantly treated shows no statistically significant interactions in its pharmacokinetic parameters

Keywords


Fluvastatin, Ticagrelor, Pharmacokinetic Parameters.

References